Korean Drug고려제약
014570 · KOSDAQ · ₩014570 · 고려제약
- Market cap
- ₩31B
- Enterprise value
- −₩5.4B
- P/E
- 28.7×
- P/B
- 0.4×
- Dividend yield
- 6.4%
- ROE
- 1.4%
- Net margin
- 1.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−38.0% from the high
₩2,740Today: ₩2,815 – ₩2,860₩4,550
Returns
- 1W−7.1%
- 1M−11.7%
- 3M−14.4%
- 6M−33.3%
- YTD−34.4%
- 1Y−33.3%
- Volume today
- 1,453
- 0.1× the 20-day average
- Traded today
- ₩4.1M
- Listed shares
- 11,000,000
- EPS (12 months)
- ₩98
- Earnings yield 3.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 27 of 100 (50 is a normal day for this stock).
- MomentumWeak-16.1% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Korean Drug stock overview
Korean Drug (고려제약, KRX: 014570) is listed on KOSDAQ, in the Biotech & Pharma sector. Founded in 1980, the company develops, manufactures and sells over-the-counter medicines, including the well-known cold remedy Haben, and prescription drugs for conditions such as epilepsy, stroke and Parkinson's disease, with its central nervous system products as its main line. Its shares closed at ₩2,820 on Oct 27, 2026, up 0.18% on the day, giving it a market value of ₩31B.
Key facts
- Market cap
- ₩31B
- Sector
- Biotech & Pharma
- Latest price change
- +0.18%
- As of
- Oct 27, 2026
- Main business
- Founded in 1980, the company develops, manufactures and sells over-the-counter medicines, including the well-known cold remedy Haben, and prescription drugs for conditions such as epilepsy, stroke and Parkinson's disease, with its central nervous system products as its main line.
Quick answers about Korean Drug
- What does Korean Drug do?
- Founded in 1980, the company develops, manufactures and sells over-the-counter medicines, including the well-known cold remedy Haben, and prescription drugs for conditions such as epilepsy, stroke and Parkinson's disease, with its central nervous system products as its main line. Its product range covers cold medicines, hematinics, CNS agents, digestive agents, dermatological products, vitamins and nutritional supplements, antibiotics, and antipyretic and anti-inflammatory drugs. It sells through pharmacy, wholesale and hospital channels in Korea as well as through overseas exports.
- What is the market cap of Korean Drug?
- The market capitalisation of Korean Drug was ₩31B at the close on Oct 27, 2026.
- When is the next earnings report from Korean Drug?
- Korean companies rarely announce results dates in advance. Based on when Korean Drug filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Founded in 1980, the company develops, manufactures and sells over-the-counter medicines, including the well-known cold remedy Haben, and prescription drugs for conditions such as epilepsy, stroke and Parkinson's disease, with its central nervous system products as its main line. Its product range covers cold medicines, hematinics, CNS agents, digestive agents, dermatological products, vitamins and nutritional supplements, antibiotics, and antipyretic and anti-inflammatory drugs. It sells through pharmacy, wholesale and hospital channels in Korea as well as through overseas exports.
Written by AI from the company's latest annual report.
- Korean name
- 고려제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 박해룡
- Founded
- Jan 1980
- Listed
- Dec 2000
- Listed shares
- 11,000,000
- Fiscal year ends
- Month 12
- Website
- www.nicepharma.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Change of CEOOct 1, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Imposition of FinesJul 10, 2026
- Report on Results of Disposal of Treasury SharesMay 19, 2026
- Treasury share sale decisionMay 18, 2026
Titles in Korean until English translations are added.
Also known as: Korean Drug / 고려제약 / 014570 / KRX:014570
Source: KRX statistical information